Physician profile
Alexander Low
NPI 1861504730
$5,979.44
in general payments reported to CMS, 2019-2025
28 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $402 · 2021: $474 · 2022: $606 · 2023: $388 · 2024: $1,298 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.71 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,436.11 | 2019-2025 | |
| Janssen Biotech, INC. | $618.09 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $469.97 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $412.04 | 2019-2025 | |
| Genzyme Corporation | $336.46 | 2022-2025 | |
| Qol Medical, LLC | $219.57 | 2019-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.91 | 2019-2025 | Xifaxan |
| Allergan, INC. | $194.63 | 2019-2020 | |
| Gilead Sciences, INC. | $191.91 | 2019-2020 | |
| Celgene Corporation | $177.25 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $133.08 | 2022-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $81.69 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $68.60 | 2025 | Iqirvo |
| Olympus America INC. | $55.45 | 2019 | |
| Lilly USA, LLC | $52.70 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $37.07 | 2025 | |
| Aimmune Therapeutics, INC. | $33.94 | 2024 | |
| Nestle Healthcare Nutrition INC. | $31.17 | 2021 | |
| Braintree Laboratories, INC. | $31.12 | 2019-2024 | Sutab |
| Boston Scientific Corporation | $30.59 | 2023 | Radial Jaw 4 |
| Daiichi Sankyo INC. | $28.77 | 2019-2022 | |
| Organon LLC | $25.06 | 2024 | |
| Ucb, INC. | $21.94 | 2019 | |
| Celltrion USA INC. | $19.80 | 2024 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $19.33 | 2024 | |
| Ardelyx, INC. | $17.24 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Low listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.